Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase.
Int J Mol Sci
; 23(14)2022 Jul 12.
Article
in English
| MEDLINE | ID: covidwho-1938837
ABSTRACT
Repurposing of existing drugs is a rapid way to find potential new treatments for SARS-CoV-2. Here, we applied a virtual screening approach using Autodock Vina and molecular dynamic simulation in tandem to screen and calculate binding energies of repurposed drugs against the SARS-CoV-2 helicase protein (non-structural protein nsp13). Amongst the top hits from our study were antivirals, antihistamines, and antipsychotics, plus a range of other drugs. Approximately 30% of our top 87 hits had published evidence indicating in vivo or in vitro SARS-CoV-2 activity. Top hits not previously reported to have SARS-CoV-2 activity included the antiviral agents, cabotegravir and RSV-604; the NK1 antagonist, aprepitant; the trypanocidal drug, aminoquinuride; the analgesic, antrafenine; the anticancer intercalator, epirubicin; the antihistamine, fexofenadine; and the anticoagulant, dicoumarol. These hits from our in silico SARS-CoV-2 helicase screen warrant further testing as potential COVID-19 treatments.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Ijms23147704
Similar
MEDLINE
...
LILACS
LIS